4
|
Habler K, Koeppl B, Bracher F, Vogeser M. Targeted profiling of 24 sulfated and non-sulfated bile acids in urine using two-dimensional isotope dilution UHPLC-MS/MS. Clin Chem Lab Med 2021; 60:220-228. [PMID: 34798689 DOI: 10.1515/cclm-2021-1111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Accepted: 11/09/2021] [Indexed: 11/15/2022]
Abstract
OBJECTIVES Bile acids serve as biomarkers for liver function and are indicators for cholestatic and hepatobiliary diseases like hepatitis, cirrhosis, and intrahepatic cholestasis of pregnancy (ICP). Sulfation and renal excretion of bile acids are important elimination steps. The power of ultra high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) allows specific profiling of primary and secondary bile acids as well as their sulfated counterparts. METHODS Twenty-four sulfated and non-sulfated primary and secondary bile acids were quantified in urine with 15 corresponding stable isotope labeled internal standards by using two-dimensional UHPLC-MS/MS. The sample preparation was based on a simple dilution with a methanolic zinc sulfate solution followed by an automated online solid phase extraction clean up. RESULTS The validation results of the method fulfilled the criteria of the European Medicine Agency (EMA) "Guideline on bioanalytical method validation". To verify fitness for purpose, 40 urine samples were analyzed which showed an average of 86% sulfation, 9.1% taurine-conjugation, 14% non-conjugation, and 77% glycine-conjugation rates. CONCLUSIONS Lossless one-pot sample preparation, automated sample purification, and high number of internal standards are major innovations of the presented profiling method, which may allow diagnostic application of BA profiling in the future.
Collapse
Affiliation(s)
- Katharina Habler
- Institute of Laboratory Medicine, University Hospital, LMU, Munich, Germany
| | - Bernhard Koeppl
- Institute of Laboratory Medicine, University Hospital, LMU, Munich, Germany
- Department of Pharmacy, Center for Drug Research, LMU, Munich, Germany
| | - Franz Bracher
- Department of Pharmacy, Center for Drug Research, LMU, Munich, Germany
| | - Michael Vogeser
- Institute of Laboratory Medicine, University Hospital, LMU, Munich, Germany
| |
Collapse
|
5
|
Wei J, Chen J, Fu L, Han L, Gao X, Sarhene M, Hu L, Zhang Y, Fan G. Polygonum multiflorum Thunb suppress bile acid synthesis by activating Fxr-Fgf15 signaling in the intestine. JOURNAL OF ETHNOPHARMACOLOGY 2019; 235:472-480. [PMID: 30528660 DOI: 10.1016/j.jep.2018.12.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/06/2018] [Revised: 11/29/2018] [Accepted: 12/05/2018] [Indexed: 06/09/2023]
Abstract
ETHNOPHARMACOLOGICAL RELEVANCE Polygonum multiflorum Thunb (Heshouwu, HSW) is commonly used in clinical medicine, while the hepatotoxicities of HSW are reported increasingly in recent years. Currently, researchers have demonstrated an essential role of Bile Acids (BAs) in liver diseases. The occurrence of hepatotoxicity cases linked to HSW are characterized by jaundice and cholestasis, suggesting an interaction that between BAs and HSW AIM OF THE STUDY: This study was designed to investigate the HSW-induced liver functional and histological changes in mice and the role of HSW on bile acid synthesis, metabolism, clearance and intestinal absorption. MATERIALS AND METHODS The mice were intragastrically (i.g.) given HSW at doses of 1.275 and 3.825 g/kg (Crude extracts /body weight) once a day for seven days. Liver function was evaluated by measuring the serum levels of enzymes and analyzing the liver histology. The LC/MS analysis was performed to quantify BAs from liver, ileum and serum. Moreover, the expression of bile metabolic-related transporters and metabolic enzymes at both protein and mRNA levels were observed to elucidate the underlying mechanisms. RESULTS Oral administration of HSW for 7 days could not cause liver damage. A significant change was observed for the concentrations of liver and serum BAs in treatment groups compared with normal control. The mRNA expression levels of bile acid excretory transporter (Bsep) and basolateral uptake transporter (Ntcp) were increased with the development of HSW. The concentrations of unconjugated BAs increased in mice intestines after the administration of HSW. Western blot and qRT-PCR analyses showed that HSW upregulated the protein and mRNA expression of Shp and Fgf15 in the ileum of the mice. CONCLUSION HSW treatment for 7days did not cause liver damage. HSW accelerated bile acid enterohepatic circulation and changed the composition of intestinal BAs, leding to the activation of Fxr-Fgf15 signal in intestines, and further inhibited the expression of Cyp7a1 in the liver.
Collapse
Affiliation(s)
- Jing Wei
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China; Key Laboratory of Pharmacology of Traditional Chinese Medicine Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, #312 Anshanxi Road, Nankai District, Tianjin 300193, China; Medical Experiment Center, The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China
| | - Jingrui Chen
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China; Key Laboratory of Pharmacology of Traditional Chinese Medicine Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, #312 Anshanxi Road, Nankai District, Tianjin 300193, China
| | - Lingling Fu
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China; Key Laboratory of Pharmacology of Traditional Chinese Medicine Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, #312 Anshanxi Road, Nankai District, Tianjin 300193, China
| | - Lifeng Han
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China; Key Laboratory of Pharmacology of Traditional Chinese Medicine Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, #312 Anshanxi Road, Nankai District, Tianjin 300193, China
| | - Xiumei Gao
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China; Key Laboratory of Pharmacology of Traditional Chinese Medicine Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, #312 Anshanxi Road, Nankai District, Tianjin 300193, China
| | - Michael Sarhene
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China; Key Laboratory of Pharmacology of Traditional Chinese Medicine Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, #312 Anshanxi Road, Nankai District, Tianjin 300193, China
| | - Limin Hu
- Tianjin State Key Laboratory of Modern Chinese Medicine, Tianjin, China; Key Laboratory of Pharmacology of Traditional Chinese Medicine Formulae, Ministry of Education, Tianjin University of Traditional Chinese Medicine, #312 Anshanxi Road, Nankai District, Tianjin 300193, China
| | - Youcai Zhang
- School of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Nankai Disctrict, Tianjin 300072, China.
| | - Guanwei Fan
- Medical Experiment Center, The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
| |
Collapse
|
8
|
Want EJ, Coen M, Masson P, Keun HC, Pearce JTM, Reily MD, Robertson DG, Rohde CM, Holmes E, Lindon JC, Plumb RS, Nicholson JK. Ultra Performance Liquid Chromatography-Mass Spectrometry Profiling of Bile Acid Metabolites in Biofluids: Application to Experimental Toxicology Studies. Anal Chem 2010; 82:5282-9. [DOI: 10.1021/ac1007078] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Affiliation(s)
- Elizabeth J. Want
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Muireann Coen
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Perrine Masson
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Hector C. Keun
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Jake T. M. Pearce
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Michael D. Reily
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Donald G. Robertson
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Cynthia M. Rohde
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Elaine Holmes
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - John C. Lindon
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Robert S. Plumb
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| | - Jeremy K. Nicholson
- Biomolecular Medicine, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, SW7 2AZ, U.K., Bristol Myers-Squibb, Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, Drug Safety Research and Development, Pfizer Global Research and Development, Chazy, New York 12921, and Waters Corporation, 34 Maple Street, Milford, Massachusetts 01757
| |
Collapse
|